Effective December 22, 2021 and during the current COVID-19 Public Health Emergency, eligible Local 4 members and dependents will be able to receive oral antiviral products when prescribed by a provider as the result of a diagnosis of COVID-19. These products are subject to quantity and age limitations. The Pfizer oral antiviral therapy has been approved by the FDA, on an emergency use authorization, for ages 12 and up; the Merck oral antiviral therapy has been approved by the FDA, on an emergency use authorization, for ages 18 and up. Member cost share will be $0 and will not apply to your calendar-year deductible (if on the Supplemental Plan). COVID-19 vaccines and booster shots will also continue to have a member cost share of $0.